“Personalized” battle against GI cancers: ASCO GI 2024 highlights
Personalized medicine is revolutionizing the field of oncology, and gastrointestinal (GI) cancers are at the forefront. While immunotherapy has made a transformational impact in many areas, it hasn’t seen the same success in GI cancers. This has led to rising recognition of cancer heterogeneity and highlighting the need for personalization for therapeutic benefit in subpopulations.
The key highlights at ASCO GI 2024 resonated with the theme of ‘Taking Personalized Care to the Next Level’ and provided a glimpse into the future of personalized medicine for GI cancers. Discover the post-conference takeaways from Inizio Advisory here.
Here’s how we help to shape the future of oncology treatments.
Jump to a slide with the slide dots.
12 Questions with Remco op den Kelder
Remco op den Kelder shares his leadership path, AI insights & vision for patient-focused pharma strategy in this Q&A with pharmaphorum.
Read moreInside ASCO® 2025: What oncologists really want from booth strategy
Congress engagement is being redefined - driven by oncologists’ learning preferences, AI integration, sustainability mandates, and smart booth design.
Read moreHow smart spaces and real-time strategy transformed ASCO® 2025
From LED walls to real-time in-booth optimization, ASCO® 2025 uncovered how we should engage and evolve the congress experience.
Read more